Evoke PharmaEVOK
13F holders, Q3 2025 (September 30)15holders +5
7new positions
2sold out
$4.97avg. 13F price*
At the end of Q3 2025, 15 institutions reported holding Evoke Pharma Inc. (EVOK) in their 13F filings, up 5 from Q2 2025. 7 opened new positions and 2 sold out. The largest holders were Morgan Stanley ($792K), Nantahala Capital Management, LLC ($736K) and Bleichroeder LP ($728K).
- Company
- Evoke Pharma Inc.
- CUSIP
- 30049G302
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $680K |
| Exits | 2 | $34K |
All 13F filers, Q2 2025 → Q3 2025: 373,482 shares bought and 14,791 shares sold, net +358,691 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Morgan Stanley | 0.00% | Add +248896.9% | 159,358 | $792K |
| Nantahala Capital Management, LLC | 0.05% | No change | 148,153 | $736K |
| Bleichroeder LP | 0.14% | Add +112.9% | 146,395 | $728K |
| National Wealth Management Group, LLC | 0.15% | New | 80,130 | $398K |
| DRW Securities, LLC | 0.01% | New | 23,742 | $118K |
| Vanguard Group Inc. | 0.00% | New | 18,759 | $93K |
| Two Sigma Securities, LLC | 0.01% | New | 10,437 | $52K |
| Osaic Holdings, Inc. | 0.00% | New | 3,010 | $16K |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 272 | $1K |
| Royal Bank of Canada | 0.00% | New | 190 | $1K |
| BlackRock, Inc. | 0.00% | No change | 122 | $606 |
| SBI Securities Co., Ltd. | 0.00% | Add +1.3% | 76 | $378 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -98.0% | 40 | $199 |
| NewEdge Advisors, LLC | 0.00% | No change | 17 | $84 |
| Bank of America Corp. | 0.00% | Add +20.0% | 12 | $60 |
"% of holder's portfolio" is EVOK's weight in each manager's 13F, not the share of Evoke Pharma Inc. the manager owns.